Less-Ventilated Energy-Efficient Buildings Reduce Indoor Air Quality, Harming Cognitive Performance

(p. D6) A new study shows that poor indoor air quality is associated with subtle impairments in a number of cognitive functions, including our ability to concentrate and process information. The study tracked 302 office workers in commercial buildings in six countries — the United States, Britain, China, India, Mexico and Thailand — for 12 months.

The scientists used monitors to measure ventilation and indoor air quality in the buildings, including levels of fine particulate matter, which includes dust and minuscule particles from smoking, cleaning products and outdoor air pollution that seeps into the building. The workers were asked to use an app to take regular cognitive tests during the workday. The tests included simple math problems, as well as a tricky color and word brain teaser called the Stroop test, in which a word like “blue” or “purple” is printed in green or red ink.  . . .

The study found that the office workers in buildings with the poorest indoor air quality tended to perform worse on the brain teasers. While the effect wasn’t dramatic, the findings add to a growing body of evidence suggesting that the air we breathe affects brain health.

. . .

“This study looked at how several factors in the indoor environment have an immediate impact on our cognitive function and performance,” said Joseph G. Allen, the director of the Harvard Healthy Buildings program and the study’s senior author. “This study shows that the air you’re breathing at your desk at that moment has an impact on how well you think.”

In the past, air quality control in buildings has been mostly focused on energy efficiency and comfort, with little consideration given to infection control or overall worker health.

. . .

Dr. Allen is the co-author of a new book, “Healthy Buildings: How Indoor Spaces Drive Performance and Productivity.” He said he’s been encouraged to see more businesses and individuals taking indoor air quality more seriously as a result of the pandemic. Recently he saw a job posting at a major company advertising for a “head of healthy buildings” in the company’s global real estate division.

“It tells you that serious companies are changing how they approach their buildings, and they’re not thinking about this as a one-off during Covid,” said Dr. Allen.

. . .

“The pressure is coming from employees, parents of kids in school, teachers — there’s a heightened level of awareness and expertise,” said Dr. Allen. “How many people were talking about MERV 13 filters prior to the pandemic? This knowledge that our indoor spaces have been underperforming is not going away. I think people are rightly frustrated and fed up with it.”

For the full story, see:

Tara Parker-Pope. “What Bad Indoor Air Could Do to Your Brain.” The New York Times (Tuesday, September 28, 2021): D6.

(Note: ellipses added.)

(Note: the online version of the story was updated Sept. 28, 2021, and has the title “Is Bad Indoor Air Dulling Your Brain?”)

The book co-authored by Allen, and mentioned above, is:

Allen, Joseph G., and John D. Macomber. Healthy Buildings: How Indoor Spaces Drive Performance and Productivity. Cambridge, MA: Harvard University Press, 2020.

Pandemic Increased Population Shift to the Exurbs

(p. A1) MURFREESBORO, Tenn.—This bucolic town 30 miles southeast of Nashville, Tenn., was once best known for its nearby Civil War battlefield and state college. Now it is one of the fastest-growing places in the country.

Surging housing costs and remote work are sending droves of people to live in new, fast-growing exurbs of metropolitan areas in the Southeast where suburban living has long been concentrated closer to the city.

Nashville, Charlotte, N.C., Charleston, S.C., and Jacksonville, Fla., are among the places getting the type of outer-ring residential development once found only around the country’s largest cities.

In 2020, net migration into a large group of exurban counties rose 37%, according to an analysis of U.S. Postal Service permanent change-of-address data by The Wall Street Journal. Nearly two-thirds of the flow came from large cities and their close-in suburbs.

Exurban areas, which include 240 counties as defined by the Brookings Institution, grew at almost twice the national rate over the past decade, a shift that began before the pandemic. There are signs it is accelerating this year as Americans prepare for an expected post-pandemic landscape where increased working from home reduces the need to commute.

Researchers differ in defining exurbs, but they gen-(p. A10)erally include the fast-growing outer fringes of large metro areas where single-family homes mix with farms and many workers have traditionally commuted a significant distance to the core of the metro area.”

For the full story, see:

Cameron McWhirter and Paul Overberg. “Pandemic Changes Swell Exurbs.” The Wall Street Journal (Monday, August 30, 2021): A1 & A10.

(Note: ellipsis added.)

(Note: the online version of the story has the date August 29, 2021, and has the title “New Life and Work Choices Revitalize Exurbs, Bringing New Strains.” The online version says that the title of the (New York?) print version was “Pandemic Stokes Exurbs Boom.” But my (National?) print version had the title “Pandemic Changes Swell Exurbs.”)

30,000 Tourists Find the Longest Queue at Shanghai Disney Is for Covid-19 Test

(p. A1) More than 30,000 visitors to the Shanghai Disneyland theme park were kept within the park’s gates on Sunday [October 31, 2021] and forced to undergo Covid-19 testing after a customer tested positive for the virus, a move that underscores China’s eradication efforts.

With fireworks exploding above them as they awaited nasal swabs, the Disney visitors became the latest Chinese residents to experience life under a “zero tolerance” policy for the virus enforced by their country’s government. Leaders there have taken stringent measures to contain pockets of the coronavirus in the country, despite criticism from business groups and a close to 80% vaccination rate.

“I never thought that the longest queue in Disneyland would be for a nucleic acid test,” one visitor said on social media.

(p. A6) Disney’s gargantuan mainland park—home to a Tomorrowland, Gardens of Imagination and Mickey Avenue—turned into a giant testing site late into Sunday evening, with guests required to be tested before being allowed to leave. The last visitor walked out at 10:30 p.m., said a Walt Disney Co. spokesman. Disney, which is a minority owner in the resort and has seen a spectrum of responses to Covid-19 at its parks around the world, had to comply with China’s local protocols, said the spokesman.

The shutdown on Sunday illustrates the lack of control Disney and other Western firms have in China, especially as officials work to clamp down Covid-19 outbreaks. The world’s largest entertainment company has yet to see park attendance return to pre-pandemic levels, and Sunday’s shutdown highlights the difficulties of reopening the global tourism economy while the threat of outbreaks still looms.

. . .

The mass testing proved a surreal scene. Videos shared by guests on social media showed swarms of people—many dressed up in Halloween costumes—queuing up for tests before they could leave. One showed the Disney evening fireworks erupting behind workers in hazmat suits conducting tests for park visitors.

For the full story, see:

Natasha Khan and Erich Schwartzel. “China Pens 30,000 Visitors In Park After Covid-19 Case.” The Wall Street Journal (Tuesday, November 2, 2021): A1 & A6.

(Note: ellipsis, and bracketed date, added.)

(Note: the online version of the story was updated Nov. 1, 2021, and has the title “China Locks 30,000 Visitors Inside Shanghai Disneyland After Covid-19 Case.”)

“People Are Now Coming to Their Own Conclusions About Covid”

(p. 3) Lauren Terry, 23, thought she would know what to do if she contracted Covid-19. After all, she manages a lab in Tucson that processes Covid tests.

But when she developed symptoms on Christmas Eve, she quickly realized she had no inside information.

“I first tried to take whatever rapid tests I could get my hands on,” Ms. Terry said. “I bought some over the counter. I got a free kit from my county library. A friend gave me a box. I think I tried five different brands.” When they all turned up negative, she took a P.C.R. test, but that too, was negative.

With clear symptoms, she didn’t believe the results. So she turned to Twitter. “I was searching for the Omicron rapid test efficacy and trying to figure out what brand works on this variant and what doesn’t and how long they take to produce results,” she said. (The Food and Drug Administration has said that rapid antigen tests may be less sensitive to the Omicron variant but has not identified any specific tests that outright fail to detect it.) “I started seeing people on Twitter say they were having symptoms and only testing positive days later. I decided not to see anybody for the holidays when I read that.”

She kept testing, and a few days after Christmas she received the result she had expected all along.

Though it’s been almost two years since the onset of the pandemic, this phase can feel more confusing than its start, in March 2020. Even P.C.R. tests, the gold standard, don’t always detect every case, especially early in the course of infection, and there is some doubt among scientists about whether rapid antigen tests perform as well with Omicron. And, the need for a 10-day isolation period was thrown into question after the Centers for Disease Control and Prevention announced that some people could leave their homes after only five days.

“The information is more confusing because the threat itself is more confusing,” said David Abramson, who directs the Center for Public Health Disaster Science at the N.Y.U. School of Global Public Health. “We used to know there was a hurricane coming at us from 50 miles away. Now we have this storm that is not well defined that could maybe create flood or some wind damage, but there are so many uncertainties, and we just aren’t sure.”

Many people are now coming to their own conclusions about Covid and how they should behave. After not contracting the virus after multiple exposures, they may conclude they can take more risks. Or if they have Covid they may choose to stay in isolation longer than the C.D.C. recommends.

And they aren’t necessarily embracing conspiracy theories. People are forming opinions after reading mainstream news articles and tweets from epidemiologists; they are looking at real-life experiences of people in their networks.

For the full story, see:

Alyson Krueger. “Covid Experts, the Self-Made Kind.” The New York Times, SundayStyles Section (Sunday, January 23, 2022): 3.

(Note: the online version of the story has the date January 21, 2022, and has the title “So You Think You’re a Covid Expert (but Are You?).”)

The Internet of Things Enables Better Indoor Air Measurement and Customization

(p. A1) “Indoor air quality is not a nice-to-have anymore—people have realized it’s essential,” says Arjun Kaicker, an architect at Zaha Hadid Architects, a London-based firm that has designed buildings around the world.

Many of the technologies bringing about this transformation are part of the oft-touted “Internet of Things.” It’s a combination of wireless, internet-connected sensors and automation, tied together by the cloud and millions of lines of code and sold as a service to solve a particular problem—in this case, the spread of communicable diseases and other air pollutants indoors.

As with other applications of the Internet of Things, such as in factories, much of the technology involved is about tying together existing systems so they can respond more dynamically to information their sensors are gathering, says Bobby George, chief digital officer of Carrier, which manufactures heating, ventilation and air-conditioning systems.

The goal is relatively simple: In more than 95% of buildings, air-conditioning systems are set on a schedule that remains largely untouched. Smart-building systems can pump more clean air into parts of an office as occupancy or other factors change throughout the day, adds Mr. George.

Wireless, battery-powered air-quality and occupancy sensors that can handle continuous monitoring are rapidly falling in price. They can be peppered throughout a building and don’t require opening up walls to connect to data and power.

. . .

In a May [2021] letter in the journal Science, 39 researchers and experts in public health, indoor air quality and engineering asserted that our understanding of transmission of respiratory infections, especially Covid-19, has progressed so rapidly that it should spur a “paradigm shift” for those responsible for the health and safety of office workers.

No longer, they continued, should people accept the idea that there is little we can do to prevent the spread of airborne infections at work. Just as we take pains to eliminate the spread of waterborne and foodborne disease, we now have the knowledge and tools to reduce the spread of germs in the air. And we should start demanding employers do something about it, they said.

To make that happen, businesses and schools should follow guidelines like those offered by the American Society of Heating, Refrigerating and Air-Conditioning Engineers, says William Bahnfleth, a professor of architectural engineering at Pennsylvania State University and the head of the committee that created these standards. Those guidelines include ensuring the right mix of fresh outdoor air and filtered indoor air, and using air filters that meet a higher standard of effectiveness.

Employees can use these types of published guidelines to inform their questions when talking to employers about returning to the office, Dr. Bahnfleth says. Similar guidelines are offered by the American Industrial Hygiene Association and the U.S. Centers for Disease Control and Prevention.

For the full story, see:

Christopher Mims. “KEYWORDS; Breath of Fresh Air.” The Wall Street Journal (Saturday, September 4, 2021): B2.

(Note: ellipsis, and bracketed year, added.)

(Note: the online version of the story has the same date as the print version, and has the title “KEYWORDS; The Pandemic Could Help Us Breathe Easier at the Office.”)

High Viral Load Increases Odds of Long Covid

(p. 18) It is one of many mysteries about long Covid: Who is more prone to developing it? Are some people more likely than others to experience physical, neurological or cognitive symptoms that can emerge, or linger for, months after their coronavirus infections have cleared?

Now, a team of researchers who followed more than 200 patients for two to three months after their Covid diagnoses report that they have identified biological factors that might help predict if a person will develop long Covid.

The study, published Tuesday [January 25, 2022] by the journal Cell, found four factors that could be identified early in a person’s coronavirus infection that appeared to correlate with increased risk of having lasting symptoms weeks later.

. . .

One of the four factors researchers identified is the level of coronavirus RNA in the blood early in the infection, an indicator of viral load. Another is the presence of certain autoantibodies — antibodies that mistakenly attack tissues in the body as they do in conditions like lupus and rheumatoid arthritis. A third factor is the reactivation of Epstein-Barr virus, a virus that infects most people, often when they are young, and then usually becomes dormant.

The final factor is having Type 2 diabetes, although the researchers and other experts said that in studies involving larger numbers of patients, it might turn out that diabetes is only one of several medical conditions that increase the risk of long Covid.

. . .

One persuasive conclusion, several experts said, was the suggestion that because patients with high viral loads early on often developed long Covid, giving people antivirals soon after diagnosis might help prevent long-term symptoms.

“The quicker one can eliminate the virus, the less likelihood of developing persistent virus or autoimmunity, which may drive long Covid,” Dr. Iwasaki said.

For the full story, see:

Pam Belluck. “New Research Hints at 4 Factors That May Increase Chances of Long Covid.” The New York Times, First Section (Sunday, January 30, 2022): 18.

(Note: ellipses, and bracketed year, added.)

(Note: the online version of the story has the date Jan. 25, 2022, and has the same title as the print version.)

The “Gold Standard” of Randomized Clinical Trials “Has Its Own Issues”

(p. R2) . . ., closely held Epic Systems Corp., maker of one of the most widely used electronic health record systems, searched a segment of its database in the spring of 2020 to find that routine breast, colon and cervical cancer screenings in the U.S. had each dropped by more than 85% during the first weeks of the Covid-19 pandemic. The report helped spur efforts to persuade people to make up for missed screenings.

But researchers have a much more ambitious vision for this data: to help guide how doctors treat individual patients in real time.

“The evidence from real-world data is a different and exciting new path,” says Jackie Gerhart, a physician who works with the informatics team at Epic. “You can get a lot of outcomes information from medical records that can help change care for individual patients.”

. . .

To be sure, patient records are observational, and thus subject to confounders and other shortcomings that can undercut their reliability in pointing to treatment options.

But the gold standard has its own issues. Randomized clinical trials, which control for differences in patient health status and other variables, are the preferred evidence to inform patient care. Yet such trials generally exclude an especially common group of patients—those with multiple ailments. Moreover, the elderly, children, women, minority groups and people who live far from medical research centers have long been underrepresented in such studies.

As a result, the highest-quality evidence that medicine produces doesn’t apply to most patients doctors see in daily practice. “There are so many clinical situations where the evidence that is needed does not exist,” says Nigam Shah, professor of medicine and biomedical data science at Stanford University Medical School.

Researchers have believed for at least a half-century that data in patient medical records could help fill the gaps.

. . .

The struggles of International Business Machines Corp.’s Watson raises [a] . . . yellow flag. It had ambitions to develop a tool for cancer doctors that would mine patient health records and thousands of pages of research from the peer-reviewed medical literature for treatment advice. But it hit walls, including accuracy and the complexity of combining data from electronic health records, billing claims and published research to provide a cohesive product. Doctors who used the service rarely changed treatment plans. IBM says it discontinued Watson for Oncology at the end of 2020.

For the full story, see:

Ron Winslow. “Mining the Gold in Patient Records.” The Wall Street Journal (Thursday, December 9, 2021): R2.

(Note: ellipses, and bracketed word, added.)

(Note: the online version of the story has the date December 3, 2021, and has the title “Medical Records Data Offers Doctors Hope of Better Patient Care.” In a couple of passages there are a few extra words in the online version, which is the version quoted above.)

Johan Hultin Self-Funded Trip to Find 1918 Flu Virus in the Permafrost

(p. B9) Dr. Hultin’s quest to find victims of the 1918 flu was sparked in 1950 by an offhand remark over lunch with a University of Iowa microbiologist, William Hale. Dr. Hale mentioned that there was just one way to figure out what caused the 1918 pandemic: finding victims buried in permafrost and isolating the virus from lungs that might be still frozen and preserved.

Dr. Hultin, a medical student in Sweden who was spending six months at the university, immediately realized that he was uniquely positioned to do just that. The previous summer, he and his first wife, Gunvor, spent weeks assisting a German paleontologist, Otto Geist, on a dig in Alaska. Dr. Geist could help him find villages in areas of permafrost that also had good records of deaths from the 1918 flu.

After persuading the university to provide him with a $10,000 stipend, Dr. Hultin set off for Alaska. It was early June 1951.

. . .

He removed still-frozen lung tissue from the victims, closed the grave and took the tissue back to Iowa, keeping it frozen on dry ice in the passenger compartment of a small plane.

Back in the lab, Dr. Hultin tried to grow the virus by injecting the lung tissue into fertilized chicken eggs — the standard way to grow flu viruses. He was caught up in the excitement of his experiment, he said, and had not thought about the possible danger of introducing a deadly virus into the world.

“I remember the sleepless nights,” he said. “I couldn’t wait for morning to come to charge into my lab and look at the eggs.”

But the virus was not growing.

He tried squirting lung tissue into the nostrils of guinea pigs, white mice and ferrets, but again he failed to revive the virus.

“The virus was dead,” he said.

Dr. Hultin never published his results but bided his time, working as a pathologist in private practice in San Francisco and hoping for another opportunity to resurrect that virus.

His chance came in 1997, when, sitting by a pool on vacation with his wife in Costa Rica, he noticed a paper published in Science by Dr. Jeffery K. Taubenberger, now chief of the viral pathogenesis and evolution section at the National Institute of Allergy and Infectious Diseases.

It reported a remarkable discovery. Dr. Taubenberger had searched a federal repository of pathology samples dating to the 1860s and found fragments of the 1918 virus in snippets of lung tissue from two soldiers who had died in that pandemic. The tissue had been removed at autopsy, wrapped in paraffin and stored in the warehouse.

Dr. Hultin immediately wrote to Dr. Taubenberger, telling him about his trip to Alaska. He offered to return to Brevig to see if he could find more flu victims.

“I remember getting that letter and thinking: ‘Gosh. This is really incredible. This is amazing,’” Dr. Taubenberger said in an interview this week. He thought the next step would be to apply for a grant for Dr. Hultin to return to Brevig. If all went well, Dr. Hultin might go back in a year or two.

Dr. Hultin had a different idea.

“I can’t go this week, but maybe I can go next week,” he told Dr. Taubenberger.

He added that he would go alone and pay for the trip himself so that there would be no objections from funding agencies, no delays, no ethics committees and no publicity.

. . .

Using the tissue Dr. Hultin provided, Dr. Taubenberger’s group published a paper that provided the genetic sequence of a crucial gene, hemagglutinin, which the virus had used to enter cells. The group subsequently used that tissue to determine the complete sequence of all eight of the virus’s genes.

. . .

Before results from the study of the Brevig woman’s virus were published, Dr. Hultin asked the villagers if they wanted the village to be identified in a news release and a journal article. They might be besieged by media. “Maybe you won’t like that,” he warned them.

The Brevig residents came to a consensus: Publish the paper and identify the village. Dr. Hultin was listed as a co-author.

For the full obituary, see:

Gina Kolata. “Dr. Johan Hultin, 97, Whose Work Helped Map 1918 Pandemic, Dies.” The New York Times (Friday, January 28, 2022): B9.

(Note: ellipses added.)

(Note: the online version of the obituary was updated January 28, 2022, and has the title “Johan Hultin, Who Found Frozen Clues to 1918 Virus, Dies at 97.”)

Gina Kolata devotes a chapter to Hultin’s search for the 1918 flu virus in her book:

Kolata, Gina. Flu: The Story of the Great Influenza Pandemic of 1918 and the Search for the Virus That Caused It. New York: Farrar, Straus & Giroux, Inc., 1999.

Instead of Centralizing With C.D.C., the Need for Speed Requires “Clinical and Commercial Labs to Create and Deploy Tests”

(p. A22) The faulty coronavirus testing kits developed by the Centers for Disease Control and Prevention in the early weeks of the pandemic were not only contaminated but had a basic design flaw, according to an internal review by the agency.

Health officials had already acknowledged that the test kits were contaminated, but the internal report, whose findings were published in PLOS ONE on Wednesday, also documented a design error that caused false positives.

. . .

The C.D.C.’s test was designed to detect three distinct regions, or target sequences, of the virus’s genetic material. The test kits contain a set of what are known as primers, which bind to and make copies of the target sequences, and probes, which produce a fluorescent signal when these copies are made, indicating that genetic material from the virus is present.

The primers and probes need to be carefully designed so that they bind to the target sequences and not to each other. In this case, that did not happen. One of the probes in the kit sometimes bound to one of the primers, producing the fluorescent signal and generating a false positive.

“It’s something that should have been caught in the design phase,” said Susan Butler-Wu, a clinical microbiologist at the Keck School of Medicine of the University of Southern California. “That’s one thing that you check for.”

. . .

The bigger lesson, Dr. Butler-Wu said, is that the responsibility for developing diagnostic tests should be distributed more widely during a public health emergency. Rather than relying on the C.D.C. to be the sole test developer, officials could also enlist clinical and commercial labs to create and deploy tests.

“It’s great that there’s all these additional checks in place, but what are you going to do when there’s a new emerging pathogen and we need to respond quickly?” she said. “I don’t think that’s a viable model for responding to a pandemic.”

For the full story, see:

Emily Anthes. “C.D.C. Finds Design Error In Testing Kits It Distributed.” The New York Times Thursday, December 16, 2021): A22.

(Note: ellipses added.)

(Note: the online version of the story has the date Dec. 15, 2021, and has the title “C.D.C. Virus Tests Were Contaminated and Poorly Designed, Agency Says.”)

The PLOS ONE article mentioned above is:

Lee, Justin S., Jason M. Goldstein, Jonathan L. Moon, Owen Herzegh, Dennis A. Bagarozzi, Jr., M. Steven Oberste, Heather Hughes, Kanwar Bedi, Dorothie Gerard, Brenique Cameron, Christopher Benton, Asiya Chida, Ausaf Ahmad, David J. Petway, Jr., Xiaoling Tang, Nicky Sulaiman, Dawit Teklu, Dhwani Batra, Dakota Howard, Mili Sheth, Wendi Kuhnert, Stephanie R. Bialek, Christina L. Hutson, Jan Pohl, and Darin S. Carroll. “Analysis of the Initial Lot of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.” PLOS ONE 16, no. 12 (Dec. 15, 2021). DOI: 10.1371/journal.pone.0260487.

Due to B Cells, Covid-19 Infection Creates Longer-Lasting Immunity than Does Just Vaccination

(p. D4) . . . among the vaccinated and boosted, getting infected with the Omicron variant also appears to be contributing to a psychological shift, as people realize they have probably gained at least a short-term natural boost to their immune system. Scientists call it “hybrid immunity,” which results from the combined protection of pre-existing vaccine antibodies and natural antibodies from a breakthrough infection.

. . .

A recent study showed that vaccinated health care workers with breakthrough infections had significantly higher levels of antibodies compared to a vaccinated control group that had not had natural infections. Fikadu Tafesse, an immunologist at Oregon Health & Science University who helped conduct the research, said that although the study was done before the Omicron wave, the findings suggest a drastically elevated level of protection after a breakthrough infection.

“Super immunity is maybe an overreach, but we know the most recent studies show there’s hybrid immunity, really due to immune players known as memory B cells,” said Anita Gupta, an adjunct assistant professor of anesthesiology and critical care medicine at Johns Hopkins University School of Medicine. “When some of the short-lived immune cells go away, these memory B cells are going to last a while.”

For the full story, see:

Dani Blum. “Your New ‘Hybrid Immunity’ Isn’t a Superpower.” The New York Times (Thursday, January 27, 2022): D4.

(Note: ellipses added.)

(Note: the online version of the story was updated Jan. 21, 2022, and has the title “I Had Breakthrough Covid. Can I Start Living Like It’s 2019?”)

The “recent study” mentioned above is:

Bates, Timothy A., Savannah K. McBride, Bradie Winders, Devin Schoen, Lydie Trautmann, Marcel E. Curlin, and Fikadu G. Tafesse. “Antibody Response and Variant Cross-Neutralization after Sars-Cov-2 Breakthrough Infection.” JAMA 327, no. 2 (Jan. 11, 2022): 179-81.

Surgical Masks Provide Wearer Modest Protection Against Infection from Covid-19

(p. A17) The first large randomized community-level study, published last month in Science, found that while generic surgical masks provided a modest (about 10%) reduction in the risk of infection from Delta, cloth masks didn’t significantly reduce risk. Masks may be even less protective against an extremely contagious variant like Omicron.

For the full commentary, see:

Daniel Halperin. “Omicron Is Spreading. Resistance Is Futile.” The Wall Street Journal (Tuesday, January 25, 2022): A17.

(Note: the online version of the commentary has the date Jan. 24, 2022, and has the same title as the print version.)

The article in Science mentioned above is:

Abaluck, Jason, Laura H. Kwong, Ashley Styczynski, Ashraful Haque, Md. Alamgir Kabir, Ellen Bates-Jefferys, Emily Crawford, Jade Benjamin-Chung, Shabib Raihan, Shadman Rahman, Salim Benhachmi, Neeti Zaman Bintee, Peter J. Winch, Maqsud Hossain, Hasan Mahmud Reza, Abdullah All Jaber, Shawkee Gulshan Momen, Aura Rahman, Faika Laz Banti, Tahrima Saiha Huq, Stephen P. Luby, and Ahmed Mushfiq Mobarak. “Impact of Community Masking on Covid-19: A Cluster-Randomized Trial in Bangladesh.” Science 375, no. 6577 (Jan. 14, 2022). DOI: 10.1126/science.abi9069.